


















The United States vs. Other Countries: Availability of Cancer Medicines Varies

The Most Favored Nation rule would set U.S. prices for medicines covered under Medicare Part B based on the pricing policies of 22 foreign governments – many of which set prices artificially low, resulting in severe access restrictions for patients.

	New Cancer Medicines Available	Average Delay in Availability of New Cancer Medicines
 Iceland*	N/A	N/A
 Israel*	N/A	N/A
 Luxembourg*	N/A	N/A
 New Zealand	29%	27 months
 Korea	45%	27 months
 Australia	49%	20 months
 Ireland	54%	23 months
 Belgium	55%	25 months
 Italy	58%	21 months
 Japan	59%	21 months
 Spain	59%	25 months
 Canada	59%	14 months
 Switzerland	60%	17 months
 Finland	61%	14 months
 Norway	62%	12 months
 Netherlands	63%	9 months
 Sweden	64%	10 months
 Denmark	64%	11 months
 France	68%	16 months
 Austria	68%	11 months
 United Kingdom	71%	12 months
 Germany	74%	11 months
 United States	96%	0-2 months

Source: PhRMA analysis of IQVIA Analytics Link and U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) data. June 2020. Note: New active substances approved by FDA, EMA and/or PMDA and first launched in any country between January 1, 2011, and December 31, 2019. *Data for Iceland, Israel and Luxembourg are currently unavailable.